MacroGenics’ Investigational Product Candidates
MacroGenics is a clinical-stage biopharmaceutical company focused on developing innovative, next-generation antibody-based therapies to improve the lives of cancer patients. The Company is advancing a broad pipeline of novel product candidates incorporating proprietary technology platforms.
MacroGenics and its collaboration partners are conducting clinical studies that explore the use of product candidates developed by MacroGenics in different cancer settings. The product candidates listed below are investigational, in that they are being evaluated in clinical trials and are not yet approved for use by regulatory authorities. Approval by regulatory authorities around the world, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), is required to make our medicine available to the patients. Therefore, our priority is to enroll patients in clinical trials in order to obtain the data required for review and approval by regulatory authorities.
MacroGenics studies that are currently recruiting patients for our investigational product candidates include: